| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5519 | Whz-04 | Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor |
|
| DCC5520 | Win-35428 | Dopamine reuptake inhibitor, also having some SERT affinity |
|
| DCC5521 | Win-64338 | B2 bradykinin receptor antagonist |
|
| DCC5522 | Withangulatin A | Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2 |
|
| DCC5523 | Wj35435 | Novel dual inhibitor of histone deacetylase and topoisomerase I |
|
| DCC5524 | Wjd008 | Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant |
|
| DCC5525 | Wms-1410 | Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen |
|
| DCC5526 | Wms-2539 | Potent uncompetitive NMDA receptor antagonist |
|
| DCC5527 | Wn1316 | Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS) |
|
| DCC5528 | Wnk-in-3 | Novel Allosteric WNK Kinase Inhibitor |
|
| DCC5529 | Wnt/hh-in-1 | Novel potent dual inhibitor of Wnt and hedgehog signalings, blocking porcupine and smoothened |
|
| DCC5530 | Wny0824 | Novel dual BRD4 and PLK1 inhibitor (IC 50 values of 109 and 22 nM, respectively), showing strong antiproliferative activity against cancer cells |
|
| DCC5531 | Wo-459 | Novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells |
|
| DCC5532 | Wp1193 | Novel inhibitor of the JAK2/STAT3 pathway |
|
| DCC5533 | Wp-871 Monohydrate | Main active metabolite of tazanolast, inhibiting dose-dependently compound 48/80-induced histamine release from rat peritoneal mast cells |
|
| DCC5534 | Wqe-134 | Novel Dual Inhibitor of Nitric Oxide and Prostaglandin E2 Production |
|
| DCC5535 | Wr99210 | Potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR) |
|
| DCC5536 | Wrr-286 | Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.6 nM |
|
| DCC5537 | Wrr-391 | Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.2 nM |
|
| DCC5538 | wrr-483 | Analog of K11777; Irriversible effective cysteine protease inhibitor with trypanocidal activity in cell culture and animal model with comparable efficacy to K11777. |
|
| DCC5539 | Ws-47-js03 | Novel potent RET kinase inhibitor with >500-fold selectivity against KDR (Kinase insert Domain Receptor) in cellular assays |
|
| DCC5540 | Ws-691 | Novel highly potent and orally active ABCB1 modulator capable of overcoming MDR, stabilizing ABCB1 by directly binding to ABCB1, stimulating the activity of ABCB1 ATPase without inhibitory activity against CYP3A4, increasing the sensitivity of SW620/Ad300 |
|
| DCC5541 | Wsj-557 | Novel xanthine oxidase inhibitor |
|
| DCC5542 | Wu-07047 | Simplified analog of the selective Gαq/11 inhibitor YM-25489 |
|
| DCC5543 | Wwl123 | Novel α/ß-hydrolase domain 6 (ABHD6) inhibitor |
|
| DCC5544 | Wx-671 | Novel urokinase inhibitor |
|
| DCC5545 | Wye-687 Dihydrochloride | Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) |
|
| DCC5546 | Wyk431 | Potent inhibitor of proliferation activity against a broad spectrum of human cancer cell lines, induces G2/M phase arrest and apoptosis through the PI3K/Akt pathway |
|
| DCC5547 | Xanthoangelol | Natural antibacterial agent against Gram-positive bacterial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecium and Enterococcus faecalis |
|
| DCC5548 | Xantholipin | Antibiotic, exhibiting strong antibacterial activities and showing potent cytotoxicity, inhibiting HSP47 gene expression produced by Streptomyces sp |
|
